Charles Pitman CFA
Stock Analyst at Barclays
(4.65)
# 865
Out of 4,579 analysts
365
Total ratings
66.9%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by Charles Pitman CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €50.00 → €60.00 | €47.23 | +27.04% | 17 | Jul 14, 2026 | |
| ETR: MRK Merck KGaA | Maintained: Hold | €130.00 → €135.00 | €141.75 | -4.76% | 19 | Jun 26, 2026 | |
| EPA: BIM bioMérieux S.A. | Maintained: Hold | €90.00 → €80.00 | €70.70 | +13.15% | 6 | Jun 23, 2026 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 670.00 | CHF 559.40 | +19.77% | 30 | Jun 22, 2026 | |
| SWX: PPGN PolyPeptide Group AG | Maintained: Buy | CHF 33.00 → CHF 40.00 | CHF 43.80 | -8.68% | 6 | Jun 16, 2026 | |
| LON: 0NZT UCB SA | Downgraded: Hold | €310.00 → €300.00 | €246.00 | +21.95% | 131 | Jun 12, 2026 | |
| SWX: BANB Bachem Holding AG | Maintained: Hold | CHF 65.00 → CHF 70.00 | CHF 73.15 | -4.31% | 12 | Jun 9, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Buy | €270.00 | €214.30 | +25.99% | 22 | Apr 23, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Maintained: Buy | €220.00 | €162.70 | +35.22% | 17 | Apr 23, 2026 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €13.50 → €12.50 | €9.85 | +26.96% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 75.00 | CHF 63.52 | +18.07% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €48.00 | €51.45 | -6.71% | 15 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $13.39 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $491.00 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €105.00 → €60.00 | €67.08 | -10.55% | 3 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €700.00 → €850.00 | €792.80 | +7.21% | 26 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €120.00 → €125.00 | €158.70 | -21.24% | 30 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $660 → $739 | $888.82 | n/a | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $20 | $7.75 | n/a | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $256.91 | n/a | 1 | Jan 13, 2022 |
Bayer Aktiengesellschaft
Jul 14, 2026
Maintained: Buy
Price Target: €50.00 → €60.00
Current: €47.23
Upside: +27.04%
Merck KGaA
Jun 26, 2026
Maintained: Hold
Price Target: €130.00 → €135.00
Current: €141.75
Upside: -4.76%
bioMérieux S.A.
Jun 23, 2026
Maintained: Hold
Price Target: €90.00 → €80.00
Current: €70.70
Upside: +13.15%
Lonza Group AG
Jun 22, 2026
Maintained: Buy
Price Target: CHF 670.00
Current: CHF 559.40
Upside: +19.77%
PolyPeptide Group AG
Jun 16, 2026
Maintained: Buy
Price Target: CHF 33.00 → CHF 40.00
Current: CHF 43.80
Upside: -8.68%
UCB SA
Jun 12, 2026
Downgraded: Hold
Price Target: €310.00 → €300.00
Current: €246.00
Upside: +21.95%
Bachem Holding AG
Jun 9, 2026
Maintained: Hold
Price Target: CHF 65.00 → CHF 70.00
Current: CHF 73.15
Upside: -4.31%
Sartorius Aktiengesellschaft
Apr 23, 2026
Maintained: Buy
Price Target: €270.00
Current: €214.30
Upside: +25.99%
Sartorius Stedim Biotech S.A.
Apr 23, 2026
Maintained: Buy
Price Target: €220.00
Current: €162.70
Upside: +35.22%
Grifols, S.A.
Apr 22, 2026
Maintained: Buy
Price Target: €13.50 → €12.50
Current: €9.85
Upside: +26.96%
Mar 11, 2026
Maintained: Hold
Price Target: CHF 75.00
Current: CHF 63.52
Upside: +18.07%
Feb 12, 2026
Upgraded: Hold
Price Target: €48.00
Current: €51.45
Upside: -6.71%
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $13.39
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $491.00
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: €105.00 → €60.00
Current: €67.08
Upside: -10.55%
Oct 31, 2025
Maintained: Buy
Price Target: €700.00 → €850.00
Current: €792.80
Upside: +7.21%
Oct 24, 2025
Maintained: Hold
Price Target: €120.00 → €125.00
Current: €158.70
Upside: -21.24%
Apr 28, 2025
Maintained: Buy
Price Target: $660 → $739
Current: $888.82
Upside: n/a
Jan 4, 2024
Upgraded: Buy
Price Target: $20
Current: $7.75
Upside: n/a
Jan 13, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $256.91
Upside: n/a